These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Cerebral differences between dopamine-resistant and dopamine-responsive Parkinson's tremor. Dirkx MF; Zach H; van Nuland A; Bloem BR; Toni I; Helmich RC Brain; 2019 Oct; 142(10):3144-3157. PubMed ID: 31509182 [TBL] [Abstract][Full Text] [Related]
7. Re-emergent tremor in Parkinson's disease: the effect of dopaminergic treatment. Belvisi D; Conte A; Cutrona C; Costanzo M; Ferrazzano G; Fabbrini G; Berardelli A Eur J Neurol; 2018 Jun; 25(6):799-804. PubMed ID: 29512863 [TBL] [Abstract][Full Text] [Related]
8. Subthalamic nucleus stimulation for Parkinson disease: benefits observed in levodopa-intolerant patients. Katayama Y; Kasai M; Oshima H; Fukaya C; Yamamoto T; Ogawa K; Mizutani T J Neurosurg; 2001 Aug; 95(2):213-21. PubMed ID: 11780890 [TBL] [Abstract][Full Text] [Related]
9. Effects of dopamine on reinforcement learning in Parkinson's disease depend on motor phenotype. van Nuland AJ; Helmich RC; Dirkx MF; Zach H; Toni I; Cools R; den Ouden HEM Brain; 2020 Dec; 143(11):3422-3434. PubMed ID: 33147621 [TBL] [Abstract][Full Text] [Related]
10. Levodopa medication improves incidental sequence learning in Parkinson's disease. Beigi M; Wilkinson L; Gobet F; Parton A; Jahanshahi M Neuropsychologia; 2016 Dec; 93(Pt A):53-60. PubMed ID: 27686948 [TBL] [Abstract][Full Text] [Related]
11. Dopamine controls Parkinson's tremor by inhibiting the cerebellar thalamus. Dirkx MF; den Ouden HE; Aarts E; Timmer MH; Bloem BR; Toni I; Helmich RC Brain; 2017 Mar; 140(3):721-734. PubMed ID: 28073788 [TBL] [Abstract][Full Text] [Related]
12. [Early treatment of Parkinson's disease with levodopa]. Odekerken VJ; Post B; Verschuur CV; de Bie RM Ned Tijdschr Geneeskd; 2009; 153():A286. PubMed ID: 19785822 [TBL] [Abstract][Full Text] [Related]
13. Effects of subthalamic nucleus stimulation and medication on resting and postural tremor in Parkinson's disease. Sturman MM; Vaillancourt DE; Metman LV; Bakay RA; Corcos DM Brain; 2004 Sep; 127(Pt 9):2131-43. PubMed ID: 15240437 [TBL] [Abstract][Full Text] [Related]
14. Assessment of rest tremor in Parkinson's disease. Budzianowska A; Honczarenko K Neurol Neurochir Pol; 2008; 42(1):12-21. PubMed ID: 18365958 [TBL] [Abstract][Full Text] [Related]
15. Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients. Kumar R; Hauser RA; Mostillo J; Dronamraju N; Graf A; Merschhemke M; Kenney C Int J Neurosci; 2016; 126(1):20-4. PubMed ID: 24007304 [TBL] [Abstract][Full Text] [Related]
16. Parkinson's disease: making the diagnosis, selecting drug therapies. Scharre DW; Mahler ME Geriatrics; 1994 Oct; 49(10):14-6, 20-3. PubMed ID: 7926845 [TBL] [Abstract][Full Text] [Related]
18. Intrajejunal levodopa infusion in advanced Parkinson's disease: long-term effects on motor and non-motor symptoms and impact on patient's and caregiver's quality of life. Fasano A; Ricciardi L; Lena F; Bentivoglio AR; Modugno N Eur Rev Med Pharmacol Sci; 2012 Jan; 16(1):79-89. PubMed ID: 22338551 [TBL] [Abstract][Full Text] [Related]
19. Resting tremor in Parkinson disease: a negative predictor of levodopa-induced dyskinesia. Kipfer S; Stephan MA; Schüpbach WM; Ballinari P; Kaelin-Lang A Arch Neurol; 2011 Aug; 68(8):1037-9. PubMed ID: 21825240 [TBL] [Abstract][Full Text] [Related]
20. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients. Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]